Free cash flow generation remains inconsistent, with margins contracting from 37.6% in 2023Q4 to 13.0% in 2025Q4, largely driven by high capital intensity and seasonal working capital requirements.
| Metric | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 | Dec'08 | Dec'07 | Dec'06 | Dec'05 | Dec'04 | Dec'03 | Dec'02 | Dec'01 | Dec'00 | Dec'99 |
|---|
| Cash from Operations | 12.13B | 9.08B | 10.26B | 10.53B | 10.52B | 7.45B | 7.74B | 5.55B | 7.38B | 7.84B | 8.92B | 7.69B | 6.95B | 8.17B | 9.32B | 9.76B | 8.52B | 8.52B | 7.12B | 6.6B | 6.39B | 4.03B | 2.26B | 1.68B | 1.82B | 1.2B | 828M |
| Operating CF Margin % | 25.97% | 20.51% | 24.65% | 25.95% | 26.86% | 19.93% | 20.58% | 15.55% | 20.37% | 22.59% | 25.59% | 24.03% | 22.22% | 22.72% | 26.58% | 28.67% | 27.69% | 29.58% | 24.37% | 22.39% | 22.44% | 25.61% | 28.15% | 22.5% | 28.02% | 20.11% | 15.48% |
| Operating CF Growth % | 33.6% | -11.47% | -2.55% | 0.04% | 41.25% | -3.81% | 39.61% | -24.83% | -5.86% | -12.13% | 15.99% | 10.58% | -14.89% | -12.32% | -4.51% | 14.61% | -0.09% | 19.75% | 7.77% | 3.3% | 58.79% | 78.04% | 34.83% | -7.74% | 51.63% | 44.81% | - |
| Net Income | 5.57B | 5.5B | 5.4B | 8.37B | 6.22B | 12.31B | 1.86B | 4.31B | 8.43B | 4.71B | 4.29B | 4.39B | 3.72B | 4.97B | 5.69B | 5.47B | 5.26B | 3.85B | 5.27B | 4.01B | 2.26B | -3.61B | 2.07B | 1.76B | 1.58B | 985M | 625M |
| Depreciation & Amortization | 6.46B | 3.59B | 3.78B | 3.42B | 3.35B | 3.3B | 7.45B | 4.28B | 3.69B | 3.3B | 4.28B | 3.78B | 5.57B | 4.91B | 5.55B | 5.13B | 5.01B | 5.99B | 4.67B | 6.11B | 5.95B | 2.52B | 389.07M | 379.28M | 301M | 241M | 236M |
| Stock-Based Compensation | 0 | 0 | 0 | 245M | 244M | 0 | 252M | 284M | 263M | 250M | 206M | 206M | 200M | 155M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Taxes | -2.75B | -802M | -1.23B | -578M | -356M | -221M | -1.75B | -727M | -909M | -542M | -1.25B | -1.27B | -1.01B | -916M | -1.86B | -1.51B | -1.17B | -1.47B | -1.48B | -2.46B | -2.1B | 0 | -15.09M | 63.85M | 75M | 0 | 0 |
| Other Non-Cash Items | 827.25M | 1.42B | 1.55B | -225M | -349M | -7.62B | 355M | -1.03B | -3.98B | -458M | 555M | -164M | -1.46B | -455M | 453M | 952M | 255M | 161M | -534.98M | -45.46M | 527.69M | 5.01B | -22.23M | 69.57M | 127M | 57M | 11M |
| Working Capital Changes | 2.03B | -615M | 764M | -707M | 1.41B | -325M | -419M | -1.28B | 148M | 828M | 1.05B | 957M | 135M | -332M | -515M | -277M | -847M | -1M | -812.76M | -1.01B | -238.94M | 111.39M | -162.78M | -595.61M | -270M | -84M | -44M |
| Change in Receivables | -1.36B | -28M | -397M | -777M | 185M | -134M | -462M | -35M | -529M | 168M | -493M | -23M | 175M | 368M | -257M | -82M | -429M | -309M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | -44.02M | -477M | -840M | -927M | -357M | -593M | -547M | -701M | -145M | -323M | -466M | -11M | -117M | -445M | -232M | -378M | -489M | -84M | -89.16M | -372.03M | -585.95M | 161.55M | -54.79M | -78.14M | -105M | 31M | -56M |
| Change in Payables | 449.17M | 789M | 402M | 452M | 451M | 86M | 169M | 270M | 577M | 447M | 241M | 478M | -124M | 67M | -87M | 28M | -336M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Investing | -2.76B | -4.41B | -6.2B | -2.08B | -7.3B | 3.59B | -1.06B | -12.87B | 639M | -2.51B | -3.26B | -3.46B | -1.27B | -1.59B | -14.7B | -3.38B | -7.29B | -2.15B | -1.72B | -790.27M | -1.1B | -14.13B | -349.37M | -1.41B | -113M | -389M | 962M |
| Capital Expenditures | -4.08B | -3.23B | -3.25B | -2.2B | -2.04B | -2.11B | -1.82B | -1.98B | -1.96B | -2.08B | -2.77B | -1.56B | -1.4B | -1.61B | -1.78B | -1.57B | -1.78B | -1.61B | -1.61B | -1.45B | -1.14B | 0 | -370.02M | -1.4B | -565M | -372M | -414M |
| CapEx % of Revenue | 8.74% | 7.3% | 7.82% | 5.43% | 5.22% | 5.66% | 4.83% | 5.54% | 5.4% | 6% | 7.95% | 4.87% | 4.47% | 4.48% | 5.08% | 4.62% | 5.81% | 5.57% | 5.52% | 4.93% | 4.01% | - | 4.61% | 18.84% | 8.71% | 6.24% | 7.74% |
| Acquisitions | 955.91M | -2.52B | 1.01B | -858M | -5.59B | 5.03B | -488M | -12.86B | -1.15B | -426M | -220M | -1.73B | -235M | -282M | -13.59B | -1.66B | -5.56B | -661M | 0 | 0 | -695.71M | -15.08B | -10.32M | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 11.74B | 1.35B | -3.87B | 1.47B | -68M | -113M | -94M | 2.1B | 3.91B | 206M | -123M | 393M | 378M | 353M | 697M | -77M | 66M | 119M | 329.9M | 1.18B | 737.93M | 952.34M | 30.97M | 26.68M | 452M | 76M | 1.38B |
| Cash from Financing | -9.26B | -5.76B | -8.05B | -5.82B | -7.06B | -6.49B | -4.19B | 3.93B | -7.9B | -4.1B | -3.6B | -5.18B | -3.73B | -4.35B | 2.89B | -4.65B | -787M | -3.81B | -4.83B | -5.85B | -5.98B | 9.22B | -1.6B | -1.59B | -483M | -471M | -238M |
| Debt Issued (Net) | 2.07B | -894M | -3.14B | -1.23B | -2.8B | -2.17B | -491M | 8.72B | -2.3B | 2.29B | 1.35B | -390M | 297M | -615M | 5.28B | -1.17B | 1.92B | 69M | -935M | -4.16B | -4.79B | 9.3B | -23.03M | 46.7M | -4M | -50M | -59M |
| Equity Issued (Net) | -5.48B | -115M | -398M | -497M | -196M | -822M | -9M | -924M | -1.84B | -2.91B | -1.78B | -1.8B | -1.64B | -177M | -1B | -246M | 168M | -1.17B | -1.51B | 356.87M | 418.78M | 8.85M | -994.13M | -1.17B | -156M | -180M | 6M |
| Dividends Paid | -5.39B | -4.7B | -4.45B | -4.17B | -4.01B | -3.94B | -3.83B | -3.77B | -3.71B | -3.76B | -3.69B | -3.68B | -3.64B | -3.49B | -1.37B | -3.14B | -2.88B | -2.71B | -2.37B | -2.04B | -1.61B | -734.73M | -581.23M | -476.49M | -323M | -241M | -178M |
| Share Repurchases | -5.68B | -302M | -593M | -497M | -382M | -822M | -9M | -1.1B | -2.16B | -2.91B | -1.78B | -1.8B | -1.64B | -823M | -1.07B | -321M | 0 | -1.23B | -1.81B | 0 | 0 | 0 | -1B | -1.17B | -163M | -183M | 0 |
| Other Financing | -472.87M | -50M | -63M | 77M | -48M | 441M | 141M | -91M | -15M | 273M | 531M | 687M | 1.26B | -72M | -17M | -104M | 0 | 0 | -5.38M | -7.78M | 0 | 641.45M | 3.18M | 4.76M | 0 | 0 | -65M |
| Net Change in Cash | 970.51M | -1.27B | -4.03B | 2.64B | -3.82B | 4.49B | 2.5B | -3.39B | 42M | 1.13B | 1.81B | -916M | 1.88B | 2.26B | -2.34B | 1.77B | 466M | 2.52B | 558.98M | -95.47M | -591.02M | -913.25M | 299.35M | -1.34B | 1.23B | 340M | 1.56B |
| Free Cash Flow | 10.14B | 5.89B | 8.64B | 8.32B | 8.48B | 5.33B | 5.93B | 3.57B | 5.42B | 5.75B | 6.15B | 6.13B | 5.56B | 6.56B | 7.54B | 8.19B | 6.73B | 6.92B | 5.5B | 5.15B | 5.25B | 4.03B | 1.89B | 272.55M | 1.25B | 827M | 414M |
| FCF Margin % | 21.71% | 13.29% | 20.76% | 20.52% | 21.64% | 14.28% | 15.75% | 10.01% | 14.97% | 16.59% | 17.64% | 19.17% | 17.76% | 18.24% | 21.5% | 24.05% | 21.89% | 24% | 18.85% | 17.46% | 18.43% | 25.61% | 23.54% | 3.66% | 19.31% | 13.87% | 7.74% |
| FCF Growth % | 72.34% | -31.87% | 3.77% | -1.82% | 58.93% | -10% | 66.05% | -34.17% | -5.77% | -6.39% | 0.24% | 10.39% | -15.29% | -12.98% | -7.93% | 21.63% | -2.7% | 25.65% | 6.89% | -1.92% | 30.41% | 112.87% | 593.96% | -78.25% | 51.51% | 99.76% | - |
| FCF per Share | 4.16 | 2.35 | 3.44 | 3.32 | 3.38 | 2.13 | 2.37 | 1.43 | 2.16 | 2.24 | 2.35 | 2.33 | 2.10 | 2.49 | 2.85 | 3.14 | 2.58 | 2.63 | 2.03 | 1.90 | 1.95 | 2.20 | 1.34 | 0.19 | 0.86 | 0.57 | 0.28 |
| FCF Conversion (FCF/Net Income) | 1.55x | 1.63x | 1.90x | 1.26x | 1.69x | 0.61x | 2.81x | 1.29x | 0.88x | 1.66x | 2.08x | 1.75x | 1.87x | 1.67x | 1.65x | 1.79x | 1.62x | 2.21x | 1.35x | 1.65x | 2.83x | 2.03x | 1.09x | 0.95x | 1.15x | 1.22x | 1.32x |
| Interest Paid | 485M | 587M | 559M | 380M | 334M | 315M | 379M | 412M | 347M | 401M | 404M | 443M | 491M | 495M | 447M | 475M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 2.88B | 3.29B | 2.62B | 2.45B | 1.28B | 2.05B | 1.7B | 2.06B | 1.73B | 2.1B | 1.71B | 2.61B | 2.37B | 2.73B | 2.81B | 3.39B | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Operational cash flow volatility
As reported in recent financial filings, Sanofi's OCF/NI ratio has exhibited extreme volatility, including a negative 4.30 multiple in 2025Q4, which suggests that net income is currently a poor proxy for the company's actual ability to generate cash from its core pharmaceutical operations.
The significant divergence between net income and operating cash flow indicates that non-cash charges and accounting adjustments are heavily influencing the bottom line. Investors should monitor whether this disconnect persists as the company navigates its portfolio simplification, as it complicates the assessment of true earnings quality.
Based on the provided cash flow data, Sanofi's free cash flow margins have fluctuated wildly, reaching a high of 37.6% in 2023Q4 before contracting to 13.0% in 2025Q4, highlighting the inherent difficulty in forecasting cash generation amidst lumpy vaccine cycles and R&D investment timing.
The erratic nature of FCF generation suggests that the company's cash flow profile is highly sensitive to seasonal working capital requirements and periodic capital expenditures. This volatility may indicate that the firm's cash-generating engine is currently more reactive to external timing factors than to steady-state operational performance.
According to historical cash flow statements, Sanofi's CapEx-to-revenue ratio has consistently hovered near 15-17%, suggesting that the firm maintains a high level of capital intensity required to support its complex biologic manufacturing infrastructure and ongoing global vaccine production capacity.
This sustained level of capital expenditure implies that the company must continue to reinvest heavily to maintain its competitive moat in specialized medicine. Analysts should evaluate whether these investments are effectively driving future revenue growth or if they represent a necessary, but margin-dilutive, cost of doing business.
As evidenced by the 2024Q2 working capital outflow of $2.6 billion, Sanofi's cash flow is frequently disrupted by significant swings in inventory and receivables, which appear to be tied to the seasonal nature of its vaccine business and government tender payment schedules.
These large, periodic working capital swings suggest that the company's cash flow is prone to sudden, temporary liquidity pressures that do not necessarily reflect long-term operational health. Investors should be cautious of interpreting these quarterly fluctuations as indicators of structural changes in the firm's collection efficiency.
Quick answers to the most common questions about buying SNY stock.
Sanofi (SNY) generated $12.13B in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Sanofi (SNY) generated $10.14B in free cash flow in 2025. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.
Sanofi (SNY) spent $4.08B on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
In 2025, Sanofi (SNY) returned $5.39B to shareholders via cash dividends and spent $5.68B on share repurchases. This shows the company's commitment to returning capital to its equity investors.